BTIG Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $26
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
BTIG analyst Jeet Mukherjee initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy rating and announces Price Target of $26.
BTIG analyst Jeet Mukherjee initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy rating and announces Price Target of $26.